Cour Pharmaceutical Development Company, Inc.

This study tests a new drug called CNP-103 in people aged 12 to 35 who were diagnosed with stage 3 type 1 diabetes within the last 6 months. The goal is to see if the drug is safe and can help control the disease. Participants will receive multiple doses of CNP-103 or a placebo o…